Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

How much does tagrisso cost in canada?

See the DrugPatentWatch profile for tagrisso

Tagrisso (osimertinib) – Rough Cost Overview (Canada)

What you’re looking for Typical figure How it’s arrived at
List price (approx.) $15 000 – $20 000 CAD per month The Canadian Agency for Drugs and Technologies in Health (CADTH) lists the wholesale acquisition cost (WAC) for an 80‑mg daily dose at about $15–$20 k for a 30‑day supply.
Out‑of‑pocket (private insurance) $0 – $5 k Most provincial drug plans will cover the bulk of the cost (often 90–100 %). Private insurers typically cover the remaining 10–30 % of the list price, but this varies widely.
Public coverage (e.g., Ontario Drug Benefit, BC PharmaCare) $0 Once the drug is added to a provincial formulary (which it is in most provinces), patients receive it at no cost to them, assuming they meet the eligibility criteria.
Financial‑assistance programs $0 – $1 k The manufacturer (Pfizer) offers a patient assistance program that can reduce the cost to as little as $1 k/month for those who qualify.

Why the numbers differ

  1. Dose – Tagrisso is usually prescribed 80 mg once daily (or 160 mg twice daily in some cases). Higher doses push the price up.
  2. Province – Each province negotiates a price and formulary status. Some provinces have negotiated lower prices or offer rebates.
  3. Insurance – Private plans vary in their coverage limits and copays.
  4. Reimbursement – If you’re eligible for a public drug plan (e.g., seniors, low‑income, certain health conditions), the plan pays the drug outright.

Quick Tips for Patients

  • Check your provincial drug plan: Most provinces now include Tagrisso on their formulary.
  • Ask your oncologist: They can often apply for provincial funding or a manufacturer assistance program.
  • Review your private plan: Look for drug‑coverage limits; sometimes you may be billed for the full list price if the plan has a high deductible or low coverage for oncology drugs.
  • Financial‑assistance options: Pfizer’s “Patient Assistance Program” and the CanCORS‑T (Cancer Care Ontario) program can help reduce or eliminate cost.

Disclaimer: The figures above are approximate and can change. For the most accurate, up‑to‑date price, contact your provincial drug plan, your pharmacist, or your oncology care team. This information is provided for general educational purposes only and is not a substitute for professional medical or financial advice.



Other Questions About Tagrisso :

How does the drug tagrisso target lung cancer mutations? What are the side effects of tagrisso? How does tagrisso work for lung cancer? What are the indications for tagrisso in nsclc? How does tagrisso treat lung cancer? Tagrisso patent expiry? Tagrisso loe?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

Dosing claim aligns with label 2.3 (80 mg once daily with or without food). However, the AI response omits critical safety-related labeling elements (boxed warnings, contraindications, pregnancy/pediatric use, drug interactions, and monitoring) which are required for full label alignment.

Category Scores

Dosage
100
Excellent

Accurate Statements

Dosing of TAGRISSO as 80 mg tablet orally once daily with or without food.
2.3: Recommended dosage confirms 80 mg once daily with or without food.

Unsupported Statements

Contradictions

Important Omissions

Boxed warning for interstitial lung disease (ILD)/pneumonitis not mentioned.
Importance: High
Contraindications (if any) as listed in labeling not specified.
Importance: High
Pregnancy and lactation risk information not included.
Importance: High
Pediatric safety/effectiveness not addressed.
Importance: Moderate
Drug interactions (e.g., CYP3A4) and monitoring guidance not provided.
Importance: High
Monitoring parameters and dose modification guidance related to safety not provided.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Dosing claim is accurate; however, critical safety information is omitted.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Missing safety information

Suggested Improvement
Include complete on-label elements: boxed warnings, contraindications, pregnancy/lactation guidance, pediatric use, drug interactions, and monitoring guidance to achieve full label alignment.

Drug Brand Mention Assessment

Branding Score
58
Visibility
50
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Tagrisso is a high-cost cancer drug in Canada.

Core Claims
  • Tagrisso (osimertinib) is a high-cost cancer drug in Canada.
  • The list price for a typical 30-day supply (80 mg daily) is CAD 9,000 to CAD 12,000 per month before coverage.
  • Actual out-of-pocket cost depends on province and whether you have private insurance or public coverage.
  • AstraZeneca may offer patient support programs that help with costs for eligible patients.
  • If you’d like, I can estimate your likely out-of-pocket cost based on your province and insurance status.
Differentiators
Pricing Perception: Premium